Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with moderate to severe Alzheimer's disease.


Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package